BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22112600)

  • 1. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
    AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome.
    Tedeschi R; Bortolin MT; Bidoli E; Zanussi S; Pratesi C; Vaccher E; Tirelli U; De Paoli P
    J Clin Virol; 2012 Apr; 53(4):297-301. PubMed ID: 22244256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
    Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
    AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.
    Vaccher E; Spina M; Talamini R; Zanetti M; di Gennaro G; Nasti G; Tavio M; Bernardi D; Simonelli C; Tirelli U
    Clin Infect Dis; 2003 Dec; 37(11):1556-64. PubMed ID: 14614680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
    Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
    J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report of AIDS-related lymphoma in South Korea.
    Kim JS; Kim SJ; Kim JS; Kim ES; Shin HJ; Chung JS; Min YH; Lee MH; Choi YJ; Bang SM; Kim JA; Cho GJ; Chi HS; Jang SS; Park CJ; Suh C; Park CW; Kim CS;
    Jpn J Clin Oncol; 2008 Feb; 38(2):134-9. PubMed ID: 18263652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count.
    Rockstroh JK; Woitas RP; Brackmann HH; Kupfer B; Kaiser R; Schneweis KE; Sudhop T; Spengler U
    Eur J Med Res; 1998 May; 3(5):223-30. PubMed ID: 9580568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
    Boulanger E; Gérard L; Gabarre J; Molina JM; Rapp C; Abino JF; Cadranel J; Chevret S; Oksenhendler E
    J Clin Oncol; 2005 Jul; 23(19):4372-80. PubMed ID: 15994147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
    van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
    AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.